The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
Clin. Cancer Res., Apr;18(8):2316-25 (2012)
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.
J. Clin. Oncol., Jul;30(19):2348-53 (2012)
Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer.
Cancer Chemother. Pharmacol., Aug;70(2):305-13 (2012)
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.
J. Clin. Oncol., Dec;27(34):5800-7 (2009)
Stable disease is a valid end point in clinical trials.
Cancer J., 15(5):374-8 (2009)
A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.
Cancer Chemother. Pharmacol., Apr;67(4):751-64 (2011)
Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin.
Clin. Cancer Res., Jan;17(2):363-71 (2011)
The evolution of phase I trials in cancer medicine: a critical review of the last decade.
Chin J Cancer., Dec;30(12):815-20 (2011)
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
Clin. Cancer Res., Dec;12(24):7406-13 (2006)
Technology insight: cytotoxic drug immunoconjugates for cancer therapy.
Nat Clin Pract Oncol., Apr;4(4):245-55 (2007)
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.
J. Clin. Oncol., Apr;25(11):1390-5 (2007)
Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer.
Clin. Cancer Res., May;13(9):2675-83 (2007)
The role of mTOR inhibitors for treatment of sarcomas.
Curr Oncol Rep., Jul;9(4):316-22 (2007)
Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study.
Cancer Chemother. Pharmacol., Oct;62(5):911-9 (2008)
First International Conference on Chemoprevention of Prostate Cancer. Overview consensus statement.
J. Urol., Feb;171(2 Pt 2):S3-4 (2004)
Development of novel alkylating drugs as anticancer agents.
Curr Opin Investig Drugs., Jun;5(6):587-91 (2004)
A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
Clin. Cancer Res., Aug;10(15):5048-57 (2004)
Targeting Bcl-2 protein expression in solid tumors and hematologic malignancies with antisense oligonucleotides.
Clin Adv Hematol Oncol., Aug;3(8):635-42, 662 (2005)
Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors.
Clin. Cancer Res., Dec;11(24 Pt 1):8728-36 (2005)
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
J. Clin. Oncol., Feb;24(4):552-62 (2006)